Immunai — Narrative Value assessment | On hold · certainty low

On hold

NARRATIVE VALUE

Certainty
●○○ low

ABCDEFG

The assessment is on hold, awaiting a build-up of confirmed evidence.= non-additive meter

As of: 2026-Q3Status: Active (drug-discovery platform; results at preclinical/clinical-support stage)Ceiling reason: No confirmed minus (a B2B drug-discovery platform where benefit to those protected—patients—is downstream/projected, with no attribution yet to an approved drug or patient outcomes; information also centers on self-reporting/partnership announcements).

History2026-Q3HHistory grows each quarter

Immunai: An AI map of the immune system to speed drug discovery—patient benefit is downstream (on hold). At present independent evidence is scarce, so the assessment is on hold. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)

Main narrative

Immunai is an Israel-born AI-bio company that tries to speed drug discovery with 'an AI map of the immune system.' In 2018, Noam Solomon and Luis Voloch—double PhDs in math and computer science and MIT postdocs—founded it, headquartered in New York and Tel Aviv. New drugs have under a 10% success rate from IND to FDA approval (often about 5%), taking over 10 years and over $2 billion—and they believe the answer to 'why the same drug works for some and not others' lies in the immune system. It maps the immune system at high resolution with single-cell multi-omics (AMICA/AMICA-OS) and uses AI to support target discovery, patient stratification and clinical-trial design. Under the banner of 'Google Maps for the immune system,' it has raised $270M, employs over 80 PhDs, and has partnered with big pharma such as AstraZeneca (multi-year, expanded), Bristol Myers Squibb, Boehringer Ingelheim, Pfizer and Teva.

One person’s story (N1)

+ A single story

A +N1 (one person’s story) will be added once an independent source is confirmed.

Positive / negative effects

+ effects

See the N1 above for the main positive story; independently verified + will be added over time.

− effects (confirmed)

No confirmed −.

Watching (unconfirmed; not counted in the assessment)

P
a
t
i
e
n
t
b
e
n
e
f
i
t
i
s
d
o
w
n
s
t
r
e
a
m
/
p
r
o
j
e
c
t
e
d
;
n
o
a
t
t
r
i
b
u
t
i
o
n
y
e
t
t
o
a
n
a
p
p
r
o
v
e
d
d
r
u
g
/
p
a
t
i
e
n
t
o
u
t
c
o
m
e
s
;
i
n
f
o
r
m
a
t
i
o
n
c
e
n
t
e
r
s
o
n
s
e
l
f
-
r
e
p
o
r
t
i
n
g
/
p
a
r
t
n
e
r
s
h
i
p
a
n
n
o
u
n
c
e
m
e
n
t
s
;
a
c
o
m
m
e
r
c
i
a
l
d
e
e
p
-
t
e
c
h
c
o
m
p
a
n
y
w
i
t
h
t
h
e
s
o
c
i
a
l
p
l
u
s
s
e
c
o
n
d
a
r
y
.

Looking ahead (not included in the assessment)

Expansion from cancer immunity to autoimmune/cardiovascular inflammation/neuroinflammation/metabolic disease; a million-person-scale immune database; an actual approved drug from partnerships.

A second look

The intended plus (delivering more effective treatments for cancer and autoimmune disease to patients faster = People) and the substance of verifiable multi-year partnerships with big pharma are genuine. But this is a B2B drug-discovery platform, and patient benefit is downstream and at the projected stage—there is not yet an approved drug its technology contributed to, nor attributable patient outcomes. Much of the information also centers on self-reporting, partnership announcements and the founders' account, and scale ≠ value applies. It is a commercial deep-tech company rather than a mission-driven social organization, and the social plus is a downstream effect. Hence a definitive A–E / out-of-scope judgment is premature, and it is on hold. To be reassessed once approvals/patient outcomes emerge.

Sources

MIT News｜Improving drug development with a vast map of the immune system｜2024-04-11｜🔗

The Jerusalem Post｜Israeli-founded AI biotech Immunai / Boehringer collaboration｜2026-06-25｜🔗

2026｜

How to read this assessment

A Independently verified +, with no confirmed −

B Leans +, with independent backing

C Mixed. A confirmed − sets the ceiling, or much is unverified

D A serious confirmed − sets the ceiling

E A serious − reaches the core of the organization

F Serious and systemic, with little redeeming +

G Only extreme cases

Out of scope An entity whose core purpose is illegal

On hold Independent evidence is scarce on both + and −

Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
The letter (assessment) and certainty (how reliable the information is) are separate axes.

This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.

Terms: Narrative Value = an assessment (A–G) of the distance between the story an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top